 |
|
Treatment of HIV/AIDS
Do the Dilemmas Only Increase?
Merle A. Sande, MD;
Allan Ronald, MD
JAMA. 2004;292:266-268.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
Physicians and other health care professionals who treat patients with human immunodeficiency virus (HIV)/AIDS are confronted daily with complex challenges. Fortunately, several articles in this theme issue of JAMA on HIV/AIDS help to increase the coping index for clinicians and researchers.
The International AIDS Society-USA (IAS-USA) report in this issue represents a biennial update of the criterion standard for HIV care.1 Experts evaluated the research, conferred, integrated new information, graded the evidence basis for their decisions (an advance over their previous reports), and provided an up-to-date document that can serve as an evidence-based foundation for guiding HIV adult care in developed countries. These new guidelines have not changed dramatically but do reflect the contribution of new drugs and make more definite judgments about the most-effective regimens while remaining relatively consistent on when to start or to switch therapy.
The same evidence-based guidelines are . . . [Full Text of this Article]
Author Affiliations: Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City (Dr Sande); Department of Internal Medicine, University of Manitoba School of Medicine, Winnipeg (Dr Ronald).
RELATED ARTICLES
Efficacy and Safety of Emtricitabine vs Stavudine in Combination Therapy in Antiretroviral-Naive Patients: A Randomized Trial
Michael S. Saag, Pedro Cahn, François Raffi, Marcelo Wolff, Daniel Pearce, Jean-Michel Molina, William Powderly, Audrey L. Shaw, Elsa Mondou, John Hinkle, Katyna Borroto-Esoda, Joseph B. Quinn, David W. Barry, Franck Rousseau, and for the FTC-301A Study Team
JAMA. 2004;292(2):180-189.
ABSTRACT
| FULL TEXT
Efficacy and Safety of Tenofovir DF vs Stavudine in Combination Therapy in Antiretroviral-Naive Patients: A 3-Year Randomized Trial
Joel E. Gallant, Schlomo Staszewski, Anton L. Pozniak, Edwin DeJesus, Jamal M. A. H. Suleiman, Michael D. Miller, Dion F. Coakley, Biao Lu, John J. Toole, Andrew K. Cheng, and for the 903 Study Group
JAMA. 2004;292(2):191-201.
ABSTRACT
| FULL TEXT
Nevirapine and Zidovudine at Birth to Reduce Perinatal Transmission of HIV in an African Setting: A Randomized Controlled Trial
Taha E. Taha, Newton I. Kumwenda, Donald R. Hoover, Susan A. Fiscus, George Kafulafula, Chiwawa Nkhoma, Samah Nour, Shu Chen, George Liomba, Paolo G. Miotti, and Robin L. Broadhead
JAMA. 2004;292(2):202-209.
ABSTRACT
| FULL TEXT
Treatment for Adult HIV Infection: 2004 Recommendations of the International AIDS Society-USA Panel
Patrick G. Yeni, Scott M. Hammer, Martin S. Hirsch, Michael S. Saag, Mauro Schechter, Charles C. J. Carpenter, Margaret A. Fischl, Jose M. Gatell, Brian G. Gazzard, Donna M. Jacobsen, David A. Katzenstein, Julio S. G. Montaner, Douglas D. Richman, Robert T. Schooley, Melanie A. Thompson, Stefano Vella, and Paul A. Volberding
JAMA. 2004;292(2):251-265.
ABSTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
A single centre cohort experience with a new once daily antiretroviral drug.
Stebbing et al.
Postgrad. Med. J. 2006;82:343-346.
ABSTRACT
| FULL TEXT
Emtricitabine and Tenofovir: Ready for Prime Time?
JWatch Infect. Diseases 2004;2004:3-3.
FULL TEXT
|
